1. The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective
- Author
-
Dario Maratea, Maria Grazia Corti, Giovanni Montini, Monica Bettio, and Francesca Venturini
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Nephrotic Syndrome ,Adolescent ,Off label ,030232 urology & nephrology ,Risk Assessment ,03 medical and health sciences ,Patient safety ,0302 clinical medicine ,Adrenal Cortex Hormones ,hemic and lymphatic diseases ,medicine ,Humans ,030212 general & internal medicine ,Hypoalbuminemia ,Child ,Adverse effect ,Proteinuria ,business.industry ,648/96 law ,Prognosis ,medicine.disease ,Reimbursement ,Regimen ,Treatment Outcome ,Italy ,Child, Preschool ,Commentary ,Drug Therapy, Combination ,Female ,Rituximab ,Patient Safety ,medicine.symptom ,business ,Nephrotic syndrome ,Dyslipidemia ,medicine.drug - Abstract
Background Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia. Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events, steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the treatment of children with nephrotic syndrome. Results Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 % CI: 3.05–9.06; p
- Published
- 2016
- Full Text
- View/download PDF